Get the Stockscreener App
1.17
3.31%
-0.04
Pre-market:
1.19
0.02
+1.71%
Vivosim Labs Inc stock is traded at $1.17, with a volume of 58,601.
It is down -3.31% in the last 24 hours and down -9.30% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$1.21
Open:
$1.19
24h Volume:
58,601
Relative Volume:
0.85
Market Cap:
$3.39M
Revenue:
$142.00K
Net Income/Loss:
$-1.23M
P/E Ratio:
2.5123
EPS:
0.4657
Net Cash Flow:
$-10.62M
1W Performance:
-1.68%
1M Performance:
-9.30%
6M Performance:
-41.21%
1Y Performance:
-24.00%
1-Day Range:
$1.15
$1.2071
1-Week Range:
$1.133
$1.26
52-Week Range:
$1.13
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.17 | 3.50M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates, Revenue UnreportedEstimate Dispersion - newsline.com
VivoSim Labs Faces Pressure: VIVS Stock Falls Over 10% as Key Support ApproachesIchimoku TK Cross - newsline.com
VIVS Q3 2025 Earnings: EPS Surprise of 10.83% Beats Estimates Amid Pre-Revenue PhaseEPS Surprise History - newsline.com
VIVS Q3 2025 Earnings: EPS Surprises to the Upside Amid Operational FocusPretax Income Report - The Legal Advocate
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherAnnual Earnings Summary - thelegaladvocate.com
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionNet Profit Margin - newsline.com
VIVS Q3 2025 Earnings: EPS Beat on Cost Management Amidst Ongoing DevelopmentEarnings Analysis - The Legal Advocate
VivoSim Labs (VIVS) Dips Slightly as Stock Tests Key Support LevelsRounding Bottom - The Legal Advocate
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs Inc. (VIVS) Edges Up 1.49% as It Tests Resistance at $1.43MESA MA - The Legal Advocate
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates Amid Unreported RevenueSocial Signal Watchlist - Newser
VIVS Stock Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VIVS Q4'25 Earnings: EPS estimate is (2.04) USD - TradingView
VIVS Stock Price, Quote & Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
Number of shareholders of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
Lobbying Update: $10,000 of VIVOSIM LABS INC. lobbying was just disclosed - Quiver Quantitative
VivoSim Labs, Inc. (VIVS) Eps Diluted (TTM) - Zacks Investment Research
What VivoSim Labs (VIVS) capital allocation tells us | Q3 2025: Better Than ExpectedGuidance Update - newser.com
VivoSim Platform Predicts Gastrointestinal Toxicity - GlobeNewswire
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewswire
VIVS Price Today: VivoSim Labs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
VIVS VivoSim Labs notches 32.1 percent Q3 2025 revenue growth, shares edge higher on narrower than expected loss.AI Stock Signals - Newser
VivoSim Labs (VIVS) Stock: Is It a Compelling Buy (-4.35%) 2026-04-20Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
VIVS Technical Analysis & ETF Price Forecast - Intellectia AI
Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Esousa Group reports 9.9% stake in VivoSim Labs (NASDAQ: VIVS) - Stock Titan
VIVS SEC FilingsVivoSim Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart
VivoSim Labs Prices Best-Efforts Public Offering - TipRanks
VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView
VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan
VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan
VIVS Stock Analysis: VivoSim Labs Inc gains 13.68 percent to 1.62 amid bullish momentum - Newser
VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm
VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia
VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - au.finance.yahoo.com
[EFFECT] VivoSim Labs, INC. SEC Filing - Stock Titan
VivoSim Labs (NASDAQ: VIVS) outlines $4M two-tranche stock and warrant financing - Stock Titan
Aug Breakouts: Is VivoSim Labs Inc benefiting from innovation trendsWeekly Gains Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-29 07:44:35 - baoquankhu1.vn
VivoSim Labs (NASDAQ: VIVS) files S-1 for $4M unit offering - Stock Titan
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing - GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Yahoo Finance
VivoSim Labs, Inc.: Fundamental Analysis and Financial Ratings | 4OR | US68620A3023 - marketscreener.com
Market Catalysts: What is the cash position of VivoSim Labs Inc2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Is VivoSim Labs Inc. stock a buy before product launchesJuly 2025 Rallies & Safe Capital Investment Plans - Naître et grandir
Buyback Watch: How much upside does VivoSim Labs Inc haveTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Why Is VIVS Stock Up 79% Today? - Stocktwits
VIVS Earnings History & Surprises | EPS & Revenue Results | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim names Raghunathan as VP of global sales By Investing.com - Investing.com Canada
Vivosim Labs Inc Stock (VIVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):